Overview

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Status:
Terminated
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a study of ABT-126 in the treatment of cognitive impairment associated with schizophrenia (CIAS), a long-term extension study to study M10-855 (NCT01655680).
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie